BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marton A, Kaneko T, Kovalik JP, Yasui A, Nishiyama A, Kitada K, Titze J. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. Nat Rev Nephrol 2021;17:65-77. [PMID: 33005037 DOI: 10.1038/s41581-020-00350-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Tang J, Ye L, Yan Q, Zhang X, Wang L. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism. Front Pharmacol 2022;13:800490. [PMID: 35281930 DOI: 10.3389/fphar.2022.800490] [Reference Citation Analysis]
2 Ebert T, Neytchev O, Witasp A, Kublickiene K, Stenvinkel P, Shiels PG. Inflammation and Oxidative Stress in Chronic Kidney Disease and Dialysis Patients. Antioxid Redox Signal 2021. [PMID: 34006115 DOI: 10.1089/ars.2020.8184] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
3 Wanner C, Galle J, Lopau K. [Kidney as pacemaker for cardiovascular aging]. Dtsch Med Wochenschr 2021;146:317-22. [PMID: 33648000 DOI: 10.1055/a-1235-0533] [Reference Citation Analysis]
4 Wang TY, Wang RF, Bu ZY, Targher G, Byrne CD, Sun DQ, Zheng MH. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol 2022. [PMID: 35013596 DOI: 10.1038/s41581-021-00519-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
5 Scholtes RA, Muskiet MHA, van Baar MJB, Hesp AC, Greasley PJ, Karlsson C, Hammarstedt A, Arya N, van Raalte DH, Heerspink HJL. Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial. Diabetes Care 2021;44:440-7. [PMID: 33318125 DOI: 10.2337/dc20-2604] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
6 Haller H. The Embarrassment of Riches: Combining SGLT2 Inhibitors and Nonsteroidal Mineralocorticoid Antagonists for the Treatment of Diabetic Kidney Disease. Am J Nephrol 2021;52:605-7. [PMID: 34530423 DOI: 10.1159/000516214] [Reference Citation Analysis]
7 Del Campo A, Perez G, Castro PF, Parra V, Verdejo HE. Mitochondrial function, dynamics and quality control in the pathophysiology of HFpEF. Biochim Biophys Acta Mol Basis Dis 2021;1867:166208. [PMID: 34214606 DOI: 10.1016/j.bbadis.2021.166208] [Reference Citation Analysis]
8 Peter S. Mitochondrial dysfunction as part of an inflammatory intermediate phenotype that drives premature ageing. J Intern Med 2021;290:231-4. [PMID: 33576538 DOI: 10.1111/joim.13243] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Groothof D, Post A, Gans ROB, Bakker SJL. Ertugliflozin, renoprotection and potential confounding by muscle wasting. Diabetologia 2021. [PMID: 34940888 DOI: 10.1007/s00125-021-05614-0] [Reference Citation Analysis]
10 McMillin SM, Pham ML, Sherrill CH. Effects of sodium-glucose cotransporter-2 inhibitors on appetite markers in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis 2021;31:2507-11. [PMID: 34167866 DOI: 10.1016/j.numecd.2021.05.005] [Reference Citation Analysis]
11 Papadimitriou L, Hernandez GA, Lennep B, Long RC, Butler J, Kalogeropoulos AP. Novel Therapies in Heart Failure with Reduced Ejection Fraction: from Soluble Guanylyl Cyclase Stimulators to Cardiac Myosin Activators. Curr Treat Options Cardio Med 2021;23. [DOI: 10.1007/s11936-021-00905-6] [Reference Citation Analysis]
12 Gessner A, Gemeinhardt A, Bosch A, Kannenkeril D, Staerk C, Mayr A, Fromm MF, Schmieder RE, Maas R. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Cardiovasc Diabetol 2022;21:4. [PMID: 34991562 DOI: 10.1186/s12933-021-01436-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Luft FC. Translating plasma sodium, stores, and hydration state from mouse to man. Eur Heart J 2022:ehac175. [PMID: 35388405 DOI: 10.1093/eurheartj/ehac175] [Reference Citation Analysis]
14 Feraille E, Sassi A, Olivier V, Arnoux G, Martin PY. Renal water transport in health and disease. Pflugers Arch 2022;474:841-52. [PMID: 35678906 DOI: 10.1007/s00424-022-02712-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Wang X, Ni J, Guo R, Li L, Su J, He F, Fan G. SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism. Heart Fail Rev 2021. [PMID: 33713009 DOI: 10.1007/s10741-021-10096-8] [Reference Citation Analysis]
16 Scholtes RA, Muskiet MH, van Baar MJ, Hesp AC, Greasley PJ, Hammarstedt A, Karlsson C, Hallow KM, Danser AJ, Heerspink HJ, van Raalte DH. The adaptive renal response for volume homeostasis during two weeks of dapagliflozin treatment in people with type 2 diabetes and preserved renal function on a sodium-controlled diet. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.02.023] [Reference Citation Analysis]
17 Rohant N, Kennedy JL; Advanced Heart Failure and Transplant Cardiology, University of California, San Francisco, CA, USA, Inova Heart and Vascular Institute, Falls Church, VA, USA. Sodium–glucose Cotransporter 2 Inhibitors’ Rise to the Backbone of Heart Failure Management: A Clinical Review. Heart International 2021;15:42. [DOI: 10.17925/hi.2021.15.1.42] [Reference Citation Analysis]
18 Cao X, Du X, Jiao H, An Q, Chen R, Fang P, Wang J, Yu B. Carbohydrate-based drugs launched during 2000−2021. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.05.020] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Shiels PG, Painer J, Natterson-Horowitz B, Johnson RJ, Miranda JJ, Stenvinkel P. Manipulating the exposome to enable better ageing. Biochem J 2021;478:2889-98. [PMID: 34319404 DOI: 10.1042/BCJ20200958] [Reference Citation Analysis]
20 Stenvinkel P, Avesani CM, Gordon LJ, Schalling M, Shiels PG. Biomimetics provides lessons from nature for contemporary ways to improve human health. J Clin Transl Sci 2021;5:e128. [PMID: 34367673 DOI: 10.1017/cts.2021.790] [Reference Citation Analysis]
21 Rossitto G, Delles C. Does Excess Tissue Sodium Storage Regulate Blood Pressure? Curr Hypertens Rep 2022. [PMID: 35192140 DOI: 10.1007/s11906-022-01180-x] [Reference Citation Analysis]
22 Luft FC. Solute excretion, metabolism, and cardio-renoprotection via two distinct mechanisms revolutionize clinical outcomes. Acta Physiol (Oxf) 2021;232:e13589. [PMID: 33249728 DOI: 10.1111/apha.13589] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Jiang B, Cheng Z, Liu F, Li Q, Fu H, Mao J. Renoprotection with sodium-glucose cotransporter-2 inhibitors in children: Known and unknown. Nephrology (Carlton) 2021. [PMID: 34545979 DOI: 10.1111/nep.13979] [Reference Citation Analysis]
24 Koç Ş. A possible follow-up method for diabetic heart failure patients. Int J Clin Pract 2021;75:e14794. [PMID: 34482595 DOI: 10.1111/ijcp.14794] [Reference Citation Analysis]
25 Kitada K, Kidoguchi S, Nakano D, Nishiyama A. Sodium/glucose cotransporter 2 and renoprotection: From the perspective of energy regulation and water conservation. J Pharmacol Sci 2021;147:245-50. [PMID: 34507633 DOI: 10.1016/j.jphs.2021.07.006] [Reference Citation Analysis]
26 Basso PJ, Andrade-Oliveira V, Câmara NOS. Targeting immune cell metabolism in kidney diseases. Nat Rev Nephrol 2021;17:465-80. [PMID: 33828286 DOI: 10.1038/s41581-021-00413-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Kovarik JJ, Morisawa N, Wild J, Marton A, Takase-Minegishi K, Minegishi S, Daub S, Sands JM, Klein JD, Bailey JL, Kovalik JP, Rauh M, Karbach S, Hilgers KF, Luft F, Nishiyama A, Nakano D, Kitada K, Titze J. Adaptive physiological water conservation explains hypertension and muscle catabolism in experimental chronic renal failure. Acta Physiol (Oxf) 2021;232:e13629. [PMID: 33590667 DOI: 10.1111/apha.13629] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
28 Feijóo-Bandín S, Aragón-Herrera A, Otero-Santiago M, Anido-Varela L, Moraña-Fernández S, Tarazón E, Roselló-Lletí E, Portolés M, Gualillo O, González-Juanatey JR, Lago F. Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models. Int J Mol Sci 2022;23:5634. [PMID: 35628443 DOI: 10.3390/ijms23105634] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Gewin LS. Sugar or Fat? Renal Tubular Metabolism Reviewed in Health and Disease. Nutrients 2021;13:1580. [PMID: 34065078 DOI: 10.3390/nu13051580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Kurata Y, Nangaku M. Dapagliflozin for the treatment of chronic kidney disease. Expert Review of Endocrinology & Metabolism. [DOI: 10.1080/17446651.2022.2099373] [Reference Citation Analysis]
31 Mogi M, Higashi Y, Bokuda K, Ichihara A, Nagata D, Tanaka A, Node K, Nozato Y, Yamamoto K, Sugimoto K, Shibata H, Hoshide S, Nishizawa H, Kario K. Annual reports on hypertension research 2020. Hypertens Res 2021. [PMID: 34650193 DOI: 10.1038/s41440-021-00766-3] [Reference Citation Analysis]
32 van Ruiten CC, Hesp AC, van Raalte DH. Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: Update on recent mechanistic insights related to kidney physiology. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.03.031] [Reference Citation Analysis]
33 Nihlén S, Frithiof R, Titze J, Kawati R, Rasmusson J, Rylander C, Pikwer A, Castegren M, Belin A, Hultström M, Lipcsey M. The Contribution of Plasma Urea to Total Osmolality During Iatrogenic Fluid Reduction in Critically Ill Patients. Function 2022;3:zqab055. [DOI: 10.1093/function/zqab055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]